Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia
Article first published online: 16 SEP 2008
© 2008 The Authors. Journal compilation © 2008 Scandinavian Society of Clinical Physiology and Nuclear Medicine
Clinical Physiology and Functional Imaging
Volume 28, Issue 6, pages 417–425, November 2008
How to Cite
Vladimirova-Kitova, L., Deneva, T., Angelova, E., Nikolov, F., Marinov, B. and Mateva, N. (2008), Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clinical Physiology and Functional Imaging, 28: 417–425. doi: 10.1111/j.1475-097X.2008.00825.x
- Issue published online: 14 OCT 2008
- Article first published online: 16 SEP 2008
- Accepted for publication Received 31 January 2008; accepted 13 August 2008
- endothelium-dependent vasodilation;
- low-density lipoprotein-cholesterol;
- total homocysteine;
Background: Little is know about the relationship between asymmetric dimethylarginine (ADMA) and percent flow-mediated dilatation (%FMD) in subjects with severe hypercholesterolemia (HH).
Aim: The aim the present study was the evaluation of the relationship of ADMA to %FMD, as well as to lipid parameters and other markers of endothelial dysfunction in newly detected subjects with severe HH.
Methods: One hundred and twenty asymptomatic patients with severe, newly detected HH and 100 controls were evaluated. The plasma level of ADMA was tested by ELISA and total homocysteine (tHcy) – through fluid chromatographic analysis. The %FMD was evaluated by the diameter of brachial artery with 7·5 MHz transducer of HP SONOS 5500.
Results: Significant difference was found between patients and controls, (P<0·05) regarding lipid total cholesterol, triglycerides, high-density lipoprotein, low-dencity lipoprotein, atherogenic indices) and non-lipid markers (ADMA, sICAM-1, sVCAM-1), as well as the endothelium dependent %FMD in contrast to flow independent vasodilation. (P>0·05) No significant difference was found between the groups with respect to tHcy, P-selectine and E-selectine. (P>0·05) A strong negative correlation was found between %FMD and ADMA. (rxy = −0·895; P<0·001), Apolipoprotein-B (rxy = −0·687; P<0·0001, tHcy (rxy = −0·560; P<0·001) and Apolipoprotein index –B/A1 (rxy = −0·518; P<0·001). The subsequent linear and multiple regression analysis selected ADMA as the most significant factor in relation to %FMD.
Conclusion: It is concluded that ADMA is the basic modulator of %FMD among all tested atherogenic risk biomarkers in in newly detected subjects with severe HH.